Instance: compositionproductmonographxyntha
InstanceOf: CompositionUvEpi
Title: "Composition - Product Monograph for Package leaflet: Xyntha® Lyophilized Powder for Reconstitution in a Vial"
Description:  "Composition - Product Monograph for Package leaflet: Xyntha® Lyophilized Powder for Reconstitution in a Vial"
Usage: #example

* identifier.system = "https://www.jordan.gov.jo/"
* identifier.value = "0d69fdcb-33cf-407f-8209-a6529856ab4f"

* status = #final

* type = https://www.jordan.gov.jo/#100000155538
* type.text = "Package Leaflet"

* date = "2020-08-01T00:00:00Z"
* author = Reference(organizationpfizercanada)
* author[+] = Reference(organizationwyeth)

* title = "Product Monograph Xyntha® Lyophilized Powder for Reconstitution in a Vial"
* language = #en

* contained
  * resourceType = "Binary"
  * id = "binarypfizerlogo"
  * contentType = #image/png
  * data = "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" 

* extension.url = "http://www.jordan.gov.jo/fhir/extension/ValidationReference"
* extension
  * valueReference
    * reference = "#binarypfizerlogo"

* section[+]
  * title = "PRODUCT MONOGRAPH"
  * code = https://www.jordan.gov.jo/#100000155538
  * code.text = "PRODUCT MONOGRAPH"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'> 
        <p style="text-align:center">
          <img src="#binarypfizerlogo" alt="Pfizer Logo"/>
        </p>

        <p style="text-align:center"><b>Xyntha<sup>®</sup></b>
        </p>
        <p style="text-align:center">Lyophilized Powder for Reconstitution in a Vial</p>
        <p
            style="text-align:center">250, 500, 1000, or 2000 IU in single-use vials and one
            pre-filled diluent syringe containing 4 mL 0.9% </p><p style="text-align:center">Sodium
            Chloride for reconstitution* </p><p style="text-align:center">Antihemophilic Factor
            (Recombinant) [BDDrFVIII]</p><p style="text-align:center">For Intravenous Injection
            </p><p style="text-align:center">Antihemorrhagic Blood Coagulation Factor VIII</p>
        <p
            style="text-align:center">Reference Market: Canada</p>
        <p> </p>
        <p> </p>
        <p> </p>
        <p style="text-align:center">Xyntha<sup>®</sup></p><p style="text-align:center">Moroctocog
            alfa</p><p style="text-align:center">Antihemophilic Factor (Recombinant) [BDDrFVIII] </p>
        <p><b>SUMMARY PRODUCT INFORMATION</b></p><table border="1">
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p><b>Route of Administration</b></p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p><b>Dosage Form / Strength</b></p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p><b>Clinically Relevant Nonmedicinal Ingredients</b></p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="2" colspan="1">
                        <p>Intravenous Infusion</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Available as 250, 500, 1000, or 2000 IU in single-use vials.</p>
                    </td>
                    <td rowspan="2" colspan="1">
                        <p>Polysorbate 80 (0.4 mg/vial ), Sucrose (12 mg/vial), L-Histidine (6
                            mg/vial), Calcium Chloride Dihydrate (1 mg/vial), Sodium Chloride (72
                            mg/vial) [after reconstitution with diluent].</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                </tr>
            </tbody>
        </table>
        <p>Xyntha is prepared by a modified process that eliminates any exogenous human- or
            animal-derived protein in the cell culture process, purification, or final formulation. 
            The purification process uses a series of chromatography steps, one of which is based on
            affinity chromatography using a synthetic peptide affinity ligand.  The process also
            includes a solvent-detergent viral inactivation step and a virus-retaining
            nanofiltration step.</p><p>The labelled potency of Xyntha is based on the European
            Pharmacopoeial chromogenic substrate assay, in which the Pfizer In-House Recombinant
            Factor VIII Potency Reference Standard has been calibrated to the WHO International
            Standard using the one-stage clotting assay.  This method of potency assignment is
            intended to harmonize Xyntha with clinical monitoring using a one-stage clotting
            assay.</p>
            <p><b>INDICATIONS AND CLINICAL USE</b></p>
            <p>Xyntha, Antihemophilic Factor
            (Recombinant) [BDDrFVIII], indicated for the control and prevention of hemorrhagic
            episodes and for routine and surgical prophylaxis in patients with hemophilia A
            (congenital factor VIII deficiency or classic hemophilia).</p><p>Xyntha does not contain
            von Willebrand factor and hence is not indicated in von Willebrand’s disease. </p>
            <p><b>Geriatrics (≥ 65 years of
            age):</b>
            </p>
            <p>Clinical studies of Xyntha did not include sufficient numbers of
            subjects aged 65 and over to determine whether they respond differently from younger
            subjects.  Other reported clinical experience has not identified differences in
            responses between the elderly and younger patients. As with any patient receiving
            Xyntha, dose selection for an elderly patient should be individualized.
                </p>
                <p><b>Pediatrics: </b></p>
                <p>Xyntha is appropriate for use in children of all
            ages, including newborns.</p>
            <p>CONTRAINDICATIONS</p>
            <p>Xyntha may be
            contraindicated in patients with a known hypersensitivity to any of the constituents of
            the preparation.  </p>
            <p>Xyntha has not been studied in patients with a known history of
            hypersensitivity to hamster proteins and may be contraindicated in these patients.
        </p>
        <p>WARNINGS AND PRECAUTIONS</p>
        <table border="1">
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"><b>Serious Warnings and Precautions</b></p>
                        <ul>
                            <li>Anaphylaxis and severe hypersensitivity reactions are possible as
                                with any intravenous protein product.   Should such reactions occur,
                                treatment with the product should be discontinued and appropriate
                                treatment should be administered. </li>
                            <li>Development of activity-neutralizing antibodies has been detected in
                                patients receiving factor VIII-containing products.   If expected
                                plasma factor VIII activity levels are not attained, or if bleeding
                                is not controlled with an appropriate dose, an assay that measures
                                factor VIII inhibitor concentration should be performed. </li>
                        </ul>
                    </td>
                </tr>
            </tbody>
        </table><p>
            <b><u>General</u></b></p><p>It is recommended that, whenever possible, every time that
            Xyntha is administered to patients the lot number of the product is documented.
                    </p><p><b><u>Effects on Ability to Drive and Use Machines</u></b>
        </p><p>No studies on the ability to drive and use machines have been performed.
                    </p><p><b><u>Carcinogenesis and Mutagenesis</u></b>
        </p><p>Xyntha has been shown to be nonmutagenic in the mouse micronucleus assay.  No other
            mutagenicity studies and no investigations on carcinogenesis, impairment of fertility or
            fetal development have been conducted.  </p><p><b><u>Drug-Drug Interactions</u></b>
        </p><p>No formal druginteraction studies have been conducted with Xyntha.  No interactions
            with other medicinal products are known. </p><p><b><u>Immune</u></b></p><p>The
            occurrence of neutralizing antibodies (inhibitors) is well known in patients receiving
            factor VIII‑containing products.  Inhibitors most commonly occur early in the treatment
            course of previously untreated patients, but have also been observed in patients who
            have previously received large amounts of factor VIII products.  All patients using
            coagulation factor VIII products, including Xyntha, should be monitored periodically for
            the development of factor VIII inhibitors.  In patients with inhibitors (especially high
            level inhibitors, above 5 Bethesda units (BU)/mL), factor VIII therapy may not be
            effective, and other therapeutic options should be considered. In addition, if expected
            factor VIII activity plasma levels are not attained, or if bleeding is not controlled
            with an appropriate dose, testing should be performed to determine if a factor VIII
            inhibitor is present.  Management of such patients should be directed by physicians with
            experience in the care of patients with hemophilia.</p><p>
            <b><u>Hypersensitivity</u></b>
        </p><p>As with any intravenous protein product, allergic type hypersensitivity reactions are
            possible.  </p><p>Patients should be informed of the early signs or symptoms of
            hypersensitivity reactions including hives (rash with itching), generalized urticaria,
            tightness of the chest, wheezing, and hypotension. </p><p>If allergic or anaphylactic
            reactions occur, administration of Xyntha should be stopped immediately, and appropriate
            medical management should be given, which may include treatment for shock.  Patients
            should be advised to discontinue use of the product and contact their hemophelia
            physicians and/or seek immediate emergency care, depending on the type and severity of
            the reaction, if any of these symptoms occur. </p><p><b><u>Special Populations</u></b>
        </p><p><b>Pregnancy and Lactation:</b>
        </p><p>No animal reproduction and lactation studies have been conducted with Xyntha.  Based
            on the rare occurrence of hemophilia A in women, experience regarding the use of factor
            VIII during pregnancy is not available<b>.</b> Xyntha should be administered to pregnant
            and lactating women only if the benefit outweighs the
            risk.</p><p><b>Pediatric:</b></p><p>Xyntha is appropriate for use in children of all
            ages, including newborns.</p><p>Safety and efficacy studies have been performed both in
            previously treated children and adolescents (N=98, ages 7-18 years) and in previously
            untreated neonates, infants, and children (N=101, ages 0-52 months).  There are no
            clinical data of previously untreated patients (PUPs) treated with ReFacto AF or XYNTHA.
            An additional ongoing clinical study is evaluating the use of Xyntha<sup>®</sup>in
            previously treated subjects under 6 years of age with moderately severe to severe
            hemophilia A.</p><p><b>Geriatrics (≥ 65 years of age):</b></p><p>Clinical studies of
            Xyntha did not include sufficient numbers of subjects aged 65 and over to determine
            whether they respond differently from younger subjects.  Other reported clinical
            experience with factor VIII products has not identified differences in responses between
            the elderly and younger patients.  As with any patient receiving Xyntha, dose selection
            for an elderly patient should be individualized. </p>
            <p>ADVERSE REACTIONS </p>
            <table border="1">
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">System Organ Class</p>
                        <p style="text-align:center">(disorder)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Very Common</p>
                        <p style="text-align:center">≥10%</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Common</p>
                        <p style="text-align:center">≥1%</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Uncommon</p>
                        <p style="text-align:center">≥0.1% and &lt;1%</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Rare</p>
                        <p style="text-align:center">≥0.01% and &lt;0.1%</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Very Rare</p>
                        <p style="text-align:center">&lt;0.01%</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Immune system disorders</p>
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Anaphylactoid reaction</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Cardiac disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Angina pectoris, tachycardia, palpitations*</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Investigations</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Lab increase for antibody to Mouse IgG (ReFacto only), Lab increase of
                            FVIII antibody, Lab increase for antibody to CHO protein, </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>CPK increased, Increased aspartate aminotransferase, Increased alanine
                            aminotransferase* </p>
                        <p>Increased bilirubin</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Nervous system</p>
                        <p>disorders </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Headache, Dizziness </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Neuropathy*, Perspiration increased, Somnolence, Taste altered</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Metabolism &amp; nutrition disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Anorexia</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Musculoskeletal and connective tissue disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Arthralgia</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Myalgia</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Vascular disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Hemorrhage, hematoma</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Flushing*, Thrombophlebitis*</p>
                        <p>Hypotension, Vasodilation</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Respiratory, thoracic &amp; mediastinal disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Cough </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Dyspnea</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Gastrointestinal disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Vomiting*, Nausea, Diarrhea, Abdominal pain</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Skin and subcutaneous tissue disorders</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p><s> </s></p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Rash</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Pruritis, Urticaria</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>General disorder &amp; administration site conditions</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Pyrexia, Chills, catheter site related reaction</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Asthenia</p>
                        <p>Injection site pain</p>
                        <p>Injection site reaction, Injection site inflammation*</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Factor VIII Inhibition† </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>FVIII Inhibition in PUPS</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>FVIII Inhibition in PTPS</p>
                    </td>
                    <td rowspan="1" colspan="1"> </td>
                    <td rowspan="1" colspan="1"> </td>
                    <td rowspan="1" colspan="1"> </td>
                </tr>
            </tbody>
        </table>
        <p><i>Adverse reaction frequencies are calculated on an event per infusion
            basis</i></p>
            <p><i>(*) = These adverse reactions were totaled from adverse events and
                hemophilia events across all studies regardless of relatedness to study drug.</i>
        </p>
        <p><i>All other adverse reactions were totaled across all studies from study
                drug-related adverse events and hemophilia events ONLY</i></p>
                <p><i>For the adverse
                reaction frequencies, surgical patients receiving continuous infusion (CI), any day
                CI is administered is considered one infusion. </i>
        </p>
        <p><i>(†) = Frequency for the Adverse Reaction Factor VIII inhibition is expressed on a
                per patient basis</i></p>
        <p>The most frequently reported treatment-emergent adverse reaction, on a per infusion
            basis, was vomiting. Most adverse reactions reported were considered mild or moderate in
            severity. </p><p>In addition, as with any intravenous protein product, allergic type
            hypersensitivity reactions are possible.  Manifestations of hypersensitivity reactions
            may include hives, generalized urticaria, tightness of the chest, wheezing, hypotension,
            and anaphylaxis. </p><p>Patients with hemophilia A may develop neutralizing antibodies
            (inhibitors) to factor VIII.  As with all coagulation factor VIII products, <b>patients
                are to be monitored for the development of inhibitors</b> that are quantified in
            Bethesda Units (BUs) using either the Bethesda assay or Bethesda assay with the Nijmegen
            modification. If such inhibitors occur, the condition may manifest itself as an
            insufficient clinical response or an unexpectedly low yield of plasma factor VIII
            activity.  In such cases, it is recommended that a specialized hemophilia center be
            contacted. </p><p>Reports of lack of effect, mainly in prophylaxis patients, have been
            received during the clinical trials and post-marketing setting.  The lack of effect
            and/or low factor VIII recovery has been reported in patients with inhibitors but also
            in patients who had no evidence of inhibitors.  The lack of effect has been described as
            bleeding into target joints, bleeding into new joints, other bleeding or a subjective
            feeling by the patient of a new onset bleeding.  In order to ensure an adequate
            therapeutic response, it is important TO INDIVIDUALLY TITRATE AND MONITOR each patient’s
            dose of Xyntha, particularly when initiating treatment with Xyntha (see WARNINGS AND
            PRECAUTIONS and DOSAGE AND ADMINISTRATION).  </p><p>If any reaction takes place that is
            thought to be related to the administration of Xyntha, the rate of infusion should be
            decreased or the infusion stopped, as dictated by the response of the patient.
            </p><p>In a clinical trial (Study 301), 32 out of 101 (32%) previously untreated
            patients treated with Xyntha manufactured by the previous process developed inhibitors:
            16 out of 101 (16%) with a titer >5 Bethesda Units (BU) and 16 out of 101 (16%) with a
            titer £5 BU.  The median number of exposure days prior to inhibitor development in these
            patients was 12 days (range 3 - 49 days).  Of the 16 high responder patients, 15
            received immune tolerance (IT) treatment.  Eleven (11) of the high responders had a
            titer of &lt;0.6 BU at their latest available test after IT.  In addition, IT treatment
            was started in 10 of the 16 low titer (£5 BU) patients, 9 of whom had titer &lt;0.6 BU
            for their latest value.  Therefore, IT had an overall efficacy of 80% (20/25), 73% for
            high-responders and 90% for low-responders.  Five (5) of the 6 remaining low responder
            patients who did not receive IT also had a titer &lt;0.6 BU for their latest value.
            </p><p>In a clinical trial of Xyntha manufactured by the previous process, one of 113
            (0.9%) previously heavily treated patients who were evaluated for efficacy in bleeding
            episodes developed a high titer inhibitor.  Inhibitor development in this patient
            occurred in the same time frame as the development of monoclonal gammopathy of uncertain
            significance.  The patient was noted initially at a local laboratory to have a
            treatment-emergent low titer inhibitor at 98 exposure days, which was confirmed at 2 BU
            at the central laboratory at 113 exposure days.  After 18 months on continued treatment
            with Xyntha, the inhibitor level rose to nearly 13 BU and a bleeding episode failed to
            respond to Xyntha treatment.  </p><p>In a pivotal phase 3 study, in which previously
            treated patients (PTPs) with hemophilia A received Xyntha for routine prophylaxis and
            on-demand treatment, 94 subjects received at least one dose of Xyntha resulting in a
            total of 6775 infusions.  In this study, the incidence of FVIII inhibitors to Xyntha was
            the primary safety endpoint.  Two patients with low titer, transient inhibitors were
            observed in these 94 patients (2.1%).  In a Bayesian statistical analysis, results from
            this study (two out of 94 subjects developed an inhibitor, 89 had 50 or more exposure
            days to XYNTHA) were used to update PTP results from prior supporting studies of
            Xyntha.  This Bayesian analysis indicates that the population (true) inhibitor rate for
            Xyntha was below a predefined acceptable value of 4.4%; the estimate of the 95% upper
            limit of the true inhibitor rate was 4.07%.  </p><p>In a pivotal phase 3 study for
            surgical prophylaxis in patients with hemophilia A (study 311), one low titer persistent
            inhibitor and one transient false-positive inhibitor were reported.  </p><p>There have
            been spontaneous postmarketing reports of high titer inhibitors developing in previously
            treated patients. </p><p>Laboratory increases in anti-FVIII antibody titers, in the
            absence of inhibitor development, have been observed in clinical trials.  In a study of
            PTPs receiving XYNTHA for routine treatment and prevention of bleeding episodes (study
            310) and for surgical prophylaxis (study 311), 1 of 94 (1%) patients, and 1 of 30 (3%)
            patients, respectively, developed anti-FVIII antibodies; these patients did not develop
            an inhibitor.  The clinical significance of these antibodies, in the absence of an
            inhibitor, is unclear.  </p><p>In clinical trials of PTPs receiving XYNTHA for routine
            treatment and prevention of bleeding episodes, 0 of 94 (0%) patients in study 310, and 3
            of 110 (3%) patients in study 306/307, developed a lab increase in anti-CHO (Chinese
            hamster ovary, the cell line which is the source of factor VIII for XYNTHA) antibody
            titer, without any apparent clinical effect.  In a study of XYNTHA for surgical
            prophylaxis (study 311) 1 of 30 (3%) patients developed a lab increase for antibody to
            CHO.  Twenty of 113 (18%) previously treated patients (PTPs) had an increase in anti-CHO
            (Chinese hamster ovary, the cell line which is the source of factor VIII for Xyntha)
            antibody titer, without any apparent clinical effect. </p>
            <p><b>DRUG INTERACTIONS</b></p>
        <p>No interactions with other medicinal products are known.  </p>
        <p>
        <b>DOSAGE AND ADMINISTRATION</b>
        </p>
        <p>Treatment with Xyntha<sup>®</sup>should be initiated under the supervision of a
            physician experienced in the treatment of hemophilia A. </p><p>Xyntha<sup>®</sup>is
            appropriate for use in adults and children including newborns. </p><p>Dosage and
            duration of treatment depend on the severity of the factor VIII deficiency, the location
            and extent of bleeding, and the patient’s clinical condition.  Individual patients may
            vary in their response to factor VIII, achieving different levels of in vivo recovery
            and demonstrating different half-lives.  Doses administered should be titrated to the
            patient’s clinical response.  In the presence of an inhibitor, higher doses or
            appropriate alternative treatment may be required.  Dosage adjustment for patients with
            renal or hepatic impairment has not been studied in clinical trials. </p><p>The number
            of units of factor VIII administered is expressed in International Units (IU), which are
            related to the current World Health Organization (WHO) international standard for factor
            VIII activity.  Factor VIII activity in plasma is expressed either as a percentage
            (relative to normal human plasma) or in IU (relative to an International Standard for
            factor VIII in plasma).  </p><p>One IU of factor VIII activity corresponds approximately
            to the quantity of factor VIII in one ml of normal human plasma.  The calculation of the
            required dosage of factor VIII is based upon the empirical finding that, on average, 1
            IU of factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dl. 
            The required dosage is determined using the following formula: </p><p><b>Required units
                = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5  (IU/kg
                per IU/dL)</b>
        </p><p>Clinical data support the use of the one-stage clotting assay for monitoring Xyntha
            therapy.</p><p>The labeled potency of Xyntha<sup>®</sup>is based on the European
            Pharmacopoeia chromogenic substrate assay in which the Pfizer In-House Recombinant
            Factor VIII Potency Reference Standard has been calibrated using a one-stage clotting
            assay.  This method of potency assignment is intended to harmonize Xyntha with clinical
            monitoring using a one-stage clotting assay. </p><p>Precise monitoring of the
            replacement therapy by means of plasma factor VIII activity assay should be considered,
            particularly for surgical intervention.</p><p><b><u>Dosing for Bleeding and
                Surgery:</u></b></p><p>In the case of the following hemorrhagic events,
            consideration should be given to maintaining the factor VIII activity at or above the
            plasma levels (in % of normal or in IU/dL) for the indicated period, as outlined in the
            following table.</p>
            <table border="1">
            <thead>
                <tr>
                    <td colspan="3" rowspan="1">
                        <p>Table 2: Maintenance of Factor VIII Activity for Various Hemorrhagic
                            Events</p>
                    </td>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Type of Hemorrhage</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Factor VIII </p>
                        <p>Level Required (% or IU/dl)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Frequency of Doses (h)/</p>
                        <p>Duration of Therapy (d)</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Minor</p>
                        <p>Early hemarthrosis, superficial muscle or soft tissue and oral bleeds</p>
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                        <p>20-40</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Repeat every 12 to 24 hours as necessary until resolved.  At least 1 day,
                            depending upon the severity of the hemorrhage.</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Moderate</p>
                        <p>Hemorrhages into muscles.  Mild head trauma capitus.  Minor operations
                            including tooth extraction.  Hemorrhages into the oral cavity.</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                        <p>30-60</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Repeat infusion every 12 - 24 hours for 3 - 4 days or until adequate
                            hemostasis is achieved.  For tooth extraction a single infusion plus
                            oral antifibrinolytic therapy within 1 hour may be sufficient.  </p>
                    </td>
                </tr>
                <tr style="mso-yfti-irow:4;mso-yfti-lastrow:yes">
                    <td rowspan="1" colspan="1">
                        <p>Major</p>
                        <p>Gastrointestinal bleeding.  Intracranial, intra-abdominal or
                            intrathoracic hemorrhages. Fractures.</p>
                        <p>Major operations.</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                        <p>60-100</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Repeat infusion every 8 - 24 hours until threat is resolved or in the
                            case of surgery, until adequate local hemostasis is achieved, then
                            continue therapy for at least another 7 days.</p>
                    </td>
                </tr>
            </tbody>
        </table><p><b><u>Dosage for Prophylaxis</u></b></p><p>Xyntha has been administered
            prophylactically in a pivotal clinical trial in adolescent and adult previously treated
            patients at a dose of 30 <u>+</u> 5 IU/kg given 3 times weekly.</p><p><b><u>Inhibitors
                </u></b>
        </p><p>Patients using factor VIII replacement therapy should be monitored for the
            development of factor VIII inhibitors.  If expected factor VIII activity plasma levels
            are not attained, or if bleeding is not controlled with an appropriate dose, an assay
            should be performed to determine if a factor VIII inhibitor is present.  In patients
            with factor VIII inhibitors, factor VIII therapy may not be effective and other
            therapeutic options should be considered.  Management of such patients should be
            directed by physicians with experience in the care of patients with hemophilia.
                    </p><p><b><u>Administration</u></b>
        </p><p>Patients should follow the specific reconstitution and administration procedures
            provided by their physicians.  For instructions, patients should follow the
            recommendations in the below <b>Administration </b>and<b> Reconstitution </b>sections. 
            The procedures below are provided as general guidelines for the reconstitution and
            administration of Xyntha.</p><p>Additional instructions are provided after
                <b>Infusion</b> section that detail the use of a Xyntha vial. </p>
                <p>Parenteral drug
            products should be inspected visually for particulate matter and discoloration prior to
            administration, whenever solution and container permit. </p>
            <p>Xyntha is administered by
            IV infusion after reconstitution of the lyophilized powder with the supplied pre-filled
            diluent (0.9% Sodium Chloride solution)
            syringe.</p>
            <p><b><u>Reconstitution</u></b></p>
            <p>Always wash your hands before
            performing the following procedures.  Use germ-free methods during the preparation
            procedures. </p>
            <p>All components used in the mixing and injection of Xyntha should be
            used as soon as possible after opening their sterile containers to minimize unnecessary
            exposure to room air.</p>
            <p>Use only the materials provided in the Xyntha kit for
            dissolving the Xyntha powder with the sodium chloride diluent.</p>
            <p>Xyntha is administered by intravenous injection after dissolving with the supplied diluent (0.9%
            sodium chloride) in the pre-filled syringe.</p><p>Note: If you use more than one vial of
            Xyntha per injection, each vial should be dissolved according to the following
            instructions.  The empty syringe should be removed leaving the vial adapter in place,
            and a separate large luer lock syringe may be used to draw back the dissolved contents
            of each vial.  Do not detach the diluent syringes or the large luer lock syringe until
            you are ready to attach the large luer lock syringe to the next vial adapter.</p>
            <ol>
            <li>Allow the vial of freeze-dried Xyntha powder and the pre-filled diluent syringe to
                reach room temperature.</li>
            <li>Remove the plastic flip-top cap from the Xyntha vial to expose the central portions
                of the rubber stopper. 
                <p style="text-align:center">
                    <img src="#binaryimage003-1537998405"/>
                    </p>
                    </li>
            <li>Wipe the top of the vial with alcohol swab, or use another antiseptic solution, and
                allow to dry.  After cleaning, do not touch the rubber stopper with your hand or
                allow it to touch any surface.If you need to use more than 1 vial to inject your
                prescribed dose, you must use a new alcohol swab for each vial.</li>
            <li>Peel back the cover from the clear plastic vial adapter package.<u>Do not remove the
                    adapter from the package</u></li>
            <li>Place the vial on a flat surface.  While holding the adapter in the package, place
                the vial adapter over the vial.  Press down firmly on the package until the adapter
                snaps into place on top of the vial, with the adapter spike penetrating the vial
                stopper. 
                <p style="text-align:center"><img src="#binaryimage004-124372563"/>
                        </p>
                        </li>
            <li>Grasp the plunger rod as shown in the diagram.  Avoid contact with the shaft of the
                plunger rod.  Attach the threaded end of the plunger rod to the diluent syringe by
                pushing and turning firmly. 
                <p style="text-align:center">
                <img src="#binaryimage006-1085115419"/>
                </p></li>
            <li>Break off the tamper-resistant, plastic-tip cap from the diluent syringe by snapping
                the perforation of the cap.  This is done by bending the cap up and down until the
                perforation is broken.  Do not touch the inside of the cap or the syringe tip.  The
                diluent syringe may need to be recapped (if the dissolved Xyntha is not used
                immediately), so place the cap on its top on a clean surface in a spot where it
                would be least likely to become contaminated. 
                <p style="text-align:center">
                <img src="#binaryimage007-1887834135"/>
                </p>
                </li>
            <li>Lift the package away from the adapter and discard the package. 
            <p style="text-align:center">
                    <img src="#binaryimage008-1358253692"/>
                </p></li>
            <li>Place the vial on a flat surface.  Connect the diluent syringe to the vial adapter
                by inserting the tip of the syringe into the adapter opening while firmly pushing
                and turning the syringe clockwise until the connection is secured. 
                <p
                    style="text-align:center">
                    <img src="#binaryimage010-240412440"/>
                </p>
            </li>
            <li>Slowly depress the plunger rod to inject all the diluent into the Xyntha vial. 
            <p
                    style="text-align:center">
                    <img src="#binaryimage012-1035983834"/>
                </p>
            </li>
            <li>With the syringe still connected to the adapter, gently swirl the contents of the
                vial until the powder is dissolved. <p>Note: The final solution should be inspected
                    visually for particulate matter before administration.  The solution should be
                    clear to slightly pearly and colorless.  If it is not, the solution should be
                    discarded and a new kit should be used.</p>
            </li>
            <li>Ensuring that the syringe plunger rod is still fully depressed, invert the vial. 
                Slowly draw the solution into the syringe. <p>Note: If you prepared more than one
                    vial of Xyntha, remove the diluent syringe from the vial adapter, leaving the
                    vial adapter attached to the vial.  Quickly attach a separate large luer lock
                    syringe and draw back the dissolved contents as instructed above.  Repeat this
                    procedure with each vial in turn.  Do not detach the diluent syringes or the
                    large luer lock syringe until you are ready to attach the large luer lock
                    syringe to the next vial adapter.</p>
                    <p style="text-align:center">
                    <img src="#binaryimage012-251481591"/>
                </p>
                </li>
            <li>
                <p>Detach the syringe from the vial adapter by gently pulling and turning the
                    syringe counterclockwise.  Discard the vial with the adapter attached.</p>
                <p>Note: If the solution is not to be used immediately, the syringe cap should be
                    carefully replaced.  Do not touch the syringe tip or the inside of the cap.</p>
            </li>
        </ol>
        <p>Xyntha should be infused within 3 hours after dissolving.  The dissolved solution may be
            stored at room temperature prior to infusion.</p>
        <p>
            <b><u>Infusion (Intravenous Injection)</u></b>
        </p><p>Xyntha, when reconstituted, contains polysorbate-80, which is known to increase the
            rate of di-(2-ethylhexyl) phthalate (DEHP) extraction from polyvinyl chloride (PVC). 
            This should be considered during the preparation and administration of Xyntha, including
            storage time elapsed in a PVC container following reconstitution.  It is important that
            the recommendations in DOSAGE AND ADMINISTRATION section be followed closely. 
            </p><p>Note: </p><p>Single vial kit: The tubing of the infusion set included with Xyntha
            vial kit does not contain DEHP. </p><p>Hospital pack: An infusion set (tubing and
            butterfly needle), sterile alcohol swabs, gauze pads and bandages are required. These
            devices are not included in the Xyntha Hospital package </p><p>You should inject Xyntha
            as instructed by your hemophilia doctor or nurse.  Once you learn how to self-infuse,
            you can follow the instructions in this insert. </p><p>Always wash your hands before
            doing the following procedures.  Germ-free methods should be used during injection.
            </p><p>Xyntha should be administered using the pre-filled diluent syringe provided or a
            single sterile disposable plastic luer-lock syringe.  In addition, the solution should
            be withdrawn from the vial using the vial adapter. </p><ol>
            <li>Attach the syringe to the luer end of the infusion set tubing and perform
                venipuncture as instructed by your hemophilia doctor or nurse. </li>
            <li>Apply a tourniquet and prepare the injection site by wiping the skin well with an
                alcohol swab. If you need to use more than 1 vial to inject your prescribed dose,
                you must use a new alcohol swab for each vial. Do not use the injection needle to
                withdraw the medicine from vial 
                <p style="text-align:center">
                <img src="#binaryimage013-244659630"/>
                </p></li>
            <li>Insert the needle on the infusion set tubing into the vein, and remove the
                tourniquet.  Infuse the reconstituted Xyntha product over several minutes. Your
                comfort level should determine the rate of infusion. 
                <p style="text-align:center">
                    <img src="#binaryimage014-39753133"/>
                </p>
                </li>
            <li>
                <p>After injecting Xyntha, remove the infusion set and discard.  The amount of drug
                    product left in the infusion set will not affect your treatment.  Dispose of all
                    unused solution, the empty vial(s), and the used needles and syringes in an
                    appropriate sharps container used for throwing away waste that might hurt others
                    if not handled properly. </p>
            </li>
        </ol><p>You should record the lot number of the product every time you use Xyntha.  The lot
            number can be found on the vial label.  The peel-off label on the vial may be used to
            record the lot number. </p><p>In the absence of incompatibility studies, reconstituted
            Xyntha should not be administered in the same tubing or container with other medicinal
            products.  Infusion kit components supplied in this carton are compatible with Xyntha
            for administration. </p><p>The reconstituted Xyntha solution does not contain a
            preservative and should be used within 3 hours of reconstitution. </p>
            <p><b>OVERDOSAGE</b>
            </p>
            <p>No symptoms case of overdose have been reported with recombinant coagulation
            factor VIII products. </p>
            <p><b>ACTION AND CLINICAL PHARMACOLOGY</b>
        </p>
        <p><b><u>Mechanism of Action</u></b>
        </p>
        <p>Xyntha is a glycoprotein with an approximate molecular mass of 170 000 Da consisting
            of 1438 amino acids.  Xyntha is a recombinant DNA-based substance which has functional
            characteristics comparable to those of endogenous factor VIII.  Activated factor VIII
            acts as a cofactor for activated factor IX accelerating the conversion of factor X to
            activated factor X.  Activated factor X converts prothrombin into thrombin.  Thrombin
            then converts fibrinogen into fibrin which forms an insoluble
                    clot.</p>
                    <p><b><u>Pharmacodynamics</u></b>
        </p>
        <p>Factor VIII is the specific clotting factor deficient in patients with hemophilia A
            (classical hemophilia).  The administration of Xyntha, Antihemophilic Factor
            (Recombinant)[BDDrFVIII] increases plasma levels of factor VIII and can temporarily
            correct the coagulation defect in these patients.  </p>
            <p><b><u>Pharmacokinetics</u></b></p>
            <p><b><u>One Stage
            Assay</u></b></p>
            <p>In a pivotal cross-over pharmacokinetic study, Xyntha was shown to
            be bioequivalent to another recombinant factor VIII product (rFVIII, Advate<sup>®</sup>)
            in 30 previously treated patients (PTPs) (³ 12 years) using the one-stage clotting
            assay.  The ratios of geometric least square means of Xyntha -to-Advate<sup>®</sup> were
            100%, 89.8% and 88.0% for K-value, AUC<sub>t</sub> and AUC<sub>¥</sub><sub>,
            </sub>respectively.  The corresponding 90% confidence intervals about the ratios of
            Xyntha to Advate<sup>®</sup> geometric means were within the bioequivalence window of
            80% to 125%, demonstrating bioequivalence of Xyntha to Advate<sup>®</sup>.
                </p>
                <p><b>Figure -1: Xyntha vs. Advate</b>
        </p><img height="231"
            src="#binaryimage016-646543884"/>
        <p>In the same study, the pharmacokinetic parameters for Xyntha were determined at baseline
            and followed-up in 25 PTPs (≥12 years) after repeated administration of Xyntha for six
            months.  At baseline, following a single 2-minute intravenous infusion of 50 IU/kg dose
            of Xyntha, plasma FVIII:C increased sharply with a mean (±SD) Cmax of 1.12 (±0.19)
            IU/mL.  Thereafter, the decline of FVIII:C exhibited biphasic disposition
            characteristics.  In the initial phase, the activity dropped at a rate consistent with
            relatively rapid but limited distribution into extravascular space.  The mean (±SD)
            steady-state volume of distribution was 65.1 (± 35.1) mL/kg.  During the terminal phase,
            the rate of decline in FVIII:C was slower than the initial phase with a mean (±SD)
            terminal elimination half-life of 11.8 (± 5.1) hours.  A comparable pharmacokinetic
            profile was obtained after repeated use for six months.  The ratios of geometric least
            square means of month 6-to-baseline pharmacokinetic were 107%, 100% and 104% for
            recovery, AUCt and AUC¥, respectively. No time-dependent changes in the pharmacokinetic
            properties of Xyntha were observed (Table 3). </p>
            <table border="1">
            <thead>
                <tr>
                    <td colspan="9" rowspan="1">
                        <p><b>TABLE 3 MEAN FACTOR VIII PHARMACOKINETIC PARAMETERS FOR 25 PTPS
                                FOLLOWING A RAPID INFUSION OF XYNTHA AT A DOSE OF 50 IU/KG</b></p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Parameter</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">C<sub>max</sub>
                            (IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                                >AUC<sub>T</sub> (hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >Half-life (hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                                >AUC<sub>∞</sub>(hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >Clearance (ml/hr/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >Mean Residence Time</p>
                        <p style="text-align:center"
                            >(hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                                >V<sub>ss</sub></p>
                        <p style="text-align:center"
                            >(ml/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >Recovery (IU/dl/IU/kg)</p>
                    </td>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Baseline</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Mean</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.12</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">13.3</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">11.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">14.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">4.21</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">16.3</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">65.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">2.23</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>SD</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.19</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">2.08</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.9</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">35.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.39</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>  Min</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.59</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">4.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">6.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">4.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">2.00</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">7.9</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">34.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.19</p>
                    </td>
                </tr>
                <tr style="mso-yfti-irow:6">
                    <td rowspan="1" colspan="1">
                        <p>Max</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >1.41</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >23.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >33.9</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >25.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >10.63</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >40.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >195.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"
                            >2.83</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">Month 6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Mean</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.24</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">13.3</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">11.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">15.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">4.04</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">19.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">67.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">2.47</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>SD</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.42</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">6.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">6.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">7.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.87</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">16.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">32.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.84</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Min</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">0.65</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.3</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.19</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">7.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">18.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">1.29</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Max</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">2.60</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">41.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">32.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">14.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">9.45</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">89.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">168.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center">5.20</p>
                    </td>
                </tr>
                <tr>
                    <td colspan="9" rowspan="1">
                        <p>Abbreviations: AUC<sub>∞</sub> = area under the plasma concentration-time
                            curve from time zero to infinity; AUCt = area under the plasma
                            concentration-time curve from zero to the last measurable concentration;
                            Cmax = peak concentration; SD=standard deviation; Vss=volume of
                            distribution at steady-state</p>
                    </td>
                </tr>
            </tbody>
        </table> In a pivotal phase III  study (Study 311) for surgical prophylaxis, XYNTHA
        pharmacokinetics were evaluated during the perioperative management of patients with
        hemophilia A who were undergoing major surgery.  At the baseline visit, all patients
        received a single dose of XYNTHA of approximately 50 IU/kg. Plasma samples were analyzed for
        FVIII activity using a validated one-stage (OS) clotting method.   Recovery data are
        available for a total of 30 patients; the mean (± standard deviation [SD]) K-value was
        2.11(± 0.43) IU/dL per IU/kg, and the mean (±SD) <i>in vivo</i> recovery value was
        101.0% (± 20%). 
        <p>
            <b><u>Chromogenic Assay</u></b>
        </p>
        <p>The labeled potency of Xyntha<sup>®</sup>manufactured by the previous process is
            based on the European Pharmacopoeia chromogenic substrate assay in which the Pfizer
            In-House Recombinant Factor VIII Potency Reference Standard has been calibrated to the
            WHO International Standard using the chromogenic substrate assay. </p><p>In a crossover
            pharmacokinetic study of eighteen (18) previously treated patients using the chromogenic
            assay, the circulating mean half-life for Xyntha manufactured by the previous process
            was 14.8 ± 5.6 hours (ranged from 7.6 - 28.5 hours), which was not statistically
            significantly different from plasma-derived Antihemophilic Factor (Human), (pdAHF),
            which had a mean half-life of 13.7 ± 3.7 hours  (ranged from 8.8 - 25.1 hours).  Mean
            incremental recovery (K-value) of Xyntha manufactured by the previous process in plasma
            was 2.4 ± 0.4 IU/dL per IU/kg (ranged from 1.9 - 3.3 IU/dL per IU/kg).  This was
            comparable to the mean incremental recovery observed in plasma for pdAHF which was 2.3 ±
            0.3 IU/dL per IU/kg (ranged from 1.7 - 2.9 IU/dL per IU/kg). </p><p>In additional
            clinical studies using Xyntha manufactured by the previous process, pharmacokinetic
            parameters measured using the chromogenic assay were determined for previously treated
            patients (PTPs) and previously untreated patients (PUPs).  In PTPs (n=101; median age 26
            ± 12 years), Xyntha manufactured by the previous process had a recovery at Week 0 of 2.4
            ± 0.4 IU/dl per IU/kg (range 1.1 to 3.8 IU/dl per IU/kg).  In measurements over 4 years
            of use (Month 3 [n=90], Month 6 [n=87], Month 12 [n=88], Month 24 [n=70], Month 36
            [n=64] and Month 48 [n=52]), the mean incremental recovery was reproducible and ranged
            from 2.3 to 2.5 IU/dl per IU/kg.  A subset of 37 study subjects had evaluable
            pharmacokinetic profiles at both baseline and Month 12.  The 90% confidence intervals
            for the ratios of the mean values of Month 12-to-baseline AUCT, AUC¥, and K-value were
            well within the bioequivalence window of 80% to 125%, demonstrating the stability of
            these pharmacokinetic parameters over 1 year.  In PUPs (n=59; median age 10 ± 8.3
            months), Xyntha manufactured by the previous process had a mean recovery at Week 0 of
            1.5 ± 0.6 IU/dl per IU/kg (range 0.2 to 2.8 IU/dl per IU/kg).  The mean incremental
            recovery for PUPs was stable over time (5 visits during a 2-year period) and ranged from
            1.5 to 1.8 IU/dL per IU/kg of Xyntha manufactured by the previous process.  Population
            pharmacokinetic modeling using data from 44 PUPs led to a mean estimated half-life of
            Xyntha manufactured by the previous process in PUPs of 8.0 ± 2.2 hours. </p><table
            border="1">
            <thead>
                <tr>
                    <td colspan="9" rowspan="1">
                        <p>Table 4: Mean Factor VIII Pharmacokinetic Parameters for 37 PTPS with
                            Both Baseline and Month 12 Pharmacokinetic Profiles Following A Rapid
                            Infusion of Xyntha manufactured by the previous process at a Dose of 50
                            IU/KG</p>
                    </td>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Parameter</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>C<sub>max</sub> (IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>AUC<sub>T</sub> (hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Half-life (hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>AUC<sub>¥</sub> (hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Clearance (ml/hr/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Mean Residence Time</p>
                        <p>(hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>V<sub>ss</sub></p>
                        <p>(ml/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>K-value (IU/dl/IU/kg)</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Baseline</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>   Mean</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.17</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>13.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>10.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>15.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.53</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>15.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>50.9</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>2.34</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>SD</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.24</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>2.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>4.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.03</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>13.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.49</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Min</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.55</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>6.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>6.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>7.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.78</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>9.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>36.9</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.10</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>   Max</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.90</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>21.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>17.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>28.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>6.60</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>24.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>99.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.80</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Parameter</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>C<sub>max</sub> (IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>AUC<sub>T</sub> (hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Half-life (hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>AUC<sub>¥</sub> (hr*IU/ml)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Clearance (ml/hr/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>Mean Residence Time</p>
                        <p>(hr)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>V<sub>ss</sub></p>
                        <p>(ml/kg)</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>K-value (IU/dl/IU/kg)</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Month 12</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p> </p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>  Mean</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.20</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>14.0</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>11.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>16.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.37</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>16.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>51.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>2.40</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>  SD</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.29</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>4.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>3.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>5.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.08</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>4.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>11.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.58</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Min</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>0.84</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>7.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>6.6</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>8.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.49</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>9.7</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>21.3</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>1.67</p>
                    </td>
                </tr>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p>Max</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>2.31</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>32.4</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>20.1</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>33.5</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>5.66</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>27.8</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>83.2</p>
                    </td>
                    <td rowspan="1" colspan="1">
                        <p>4.61</p>
                    </td>
                </tr>
            </tbody>
        </table>
        <p><b>STORAGE AND STABILITY</b>
        </p>
        <p>Xyntha Antihemophilic Factor (Recombinant) should be stored under refrigeration at a
            temperature of 2° to 8°C.  Xyntha vial may also be stored at room temperature not to
            exceed 25°C for up to 3 months.  The diluent syringe should be stored at 2° to 25°C and
            should not be used subsequent to expiration of the Xyntha drug product.  The patient
            should write in the space provided on the outer carton the date the product was placed
            at room temperature.  After room temperature storage, the product can be returned to
            refrigerated storage until the expiration date. Do not store Xyntha vial at room
            temperature and return it to refrigerated storage more than once.  Do not use Xyntha
            vial after the expiry date on the label. </p><p><u>Product after reconstitution:</u> 
            The reconstituted solution may be stored at room temperature prior to administration. 
            The product does not contain a preservative and should be used within 3 hours.
                </p>
                <p><b>SPECIAL HANDLING INSTRUCTIONS</b>
        </p>
        <p>Freezing should be avoided to prevent damage to the pre-filled diluent syringe. 
            During storage, avoid prolonged exposure of Xyntha vial to light. </p>
            <p>DOSAGE
                FORMS, COMPOSITION AND PACKAGING
        </p>
        <p>Xyntha, Antihemophilic Factor (Recombinant) freeze-dried is supplied in kits that
            include single-use vials that contain nominally 250, 500, 1000, or 2000 IU per vial.
            Actual factor VIII activity in IU is stated on the label of each Xyntha Antihemophilic
            Factor (Recombinant) vial. </p>
            <p>In addition, each Xyntha Antihemophilic Factor
            (Recombinant) kit contains: </p>
            <ul>
            <li>1 pre-filled diluent syringe containing 4 mL 0.9% Sodium Chloride with plunger rod
                for assembly</li>
            <li>1 vial adapter.</li>
            <li>1 sterile infusion set</li>
            <li>2 alcohol swabs</li>
            <li>1 bandage</li>
            <li>1 gauze </li>
            <li>1 package insert. </li>
        </ul>
        <p>Xyntha Antihemophilic Factor (Recombinant) can also be supplied in a Hospital pack
            kit containing:</p><ul>
            <li>3vials of Xyntha powder</li>
            <li>3 pre-filled diluent syringes containing 4 mL 0.9% Sodium Chloride with plunger rod
                for assembly,</li>
            <li>3 plunger rods for the syringe</li>
            <li>3 vial adapters </li>
            <li>1 package insert. </li>
        </ul>
        <p>Xyntha Hospital pack does not contain:</p>
        <ul>
            <li>sterile infusion set (tubing and butterfly needle)</li>
            <li>alcohol swabs </li>
            <li>bandage</li>
            <li>gauze</li>
        </ul>
        <p>Not all strengths/pack sizes may be marketed. </p><p><b>Last revised:</b>  April
            2016 </p>
            <p><b>Marketing Authorization Holder:</b>
        </p>
        <p>Pfizer Canada ULC. </p>
        <p>17300 Trans-Canada Highway </p>
        <p>Kirkland, Quebec
            </p><p>Canada, H9J 2M5 </p>
            <p><b>Manufactured, Packaged and Released By:</b>
        </p>
        <p>Wyeth Farma, S.A. </p>
        <p>Autovia del Norte A-1, Km 23 </p>
        <p>Desvio Algete, Km 1,
            </p><p>28700 San Sebastian de los Reyes </p>
            <p>Madrid, Spain</p>
            <table>
            <tbody>
                <tr>
                    <td rowspan="1" colspan="1">
                        <p style="text-align:center"><b>THIS IS A MEDICAMENT</b></p>
                        <ul>
                            <li>Medicament is a product which affects your health and its
                                consumption contrary to instructions is dangerous for you.</li>
                            <li>Follow strictly the doctor’s prescription, the method of use and the
                                instructions of the Pharmacist who sold the medicament.</li>
                            <li>The doctor and the Pharmacist are experts in medicines, their
                                benefits and risks.</li>
                            <li>Do not by yourself interrupt the period of treatment
                                prescribed.</li>
                            <li>Do not repeat the same prescription without consulting your
                                doctor.</li>
                        </ul>
                        <p style="text-align:center"><b>Keep all medicaments out of reach and sight
                                of children</b></p>
                        <p><b>Council of Arab Health Ministers</b></p>
                        <p><b>Union of Arabic Pharmacists</b></p>
                    </td>
                </tr>
            </tbody>
        </table>
  </div>""" 